A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease. Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study

Journal of the American College of Cardiology

Volumn 51, Issue 16, 2008, Pages 1543-1552

  Krucoff, Mitchell W ^a   Kereiakes, Dean J ^b   Petersen, John L ^a   Mehran, Roxana ^c   Hasselblad, Vic ^a   Lansky, Alexandra J ^d   Fitzgerald, Peter J ^e   Garg, Jyotsna ^a   Turco, Mark A ^f   Simonton III, Charles A ^g   Verheye, Stefan ^h   Dubois, Christophe L ⁱ   Gammon, Roger ^j   Batchelor, Wayne B ^k   O'Shaughnessy, Charles D ^l   Hermiller Jr , James B ^m   Schofer, Joachim ⁿ   Buchbinder, Maurice ^o   Wijns, William ^p  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b The Carl & Edyth Lindner Center for Research & Education   (United States)

^c New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^d CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^f WASHINGTON HOSPITAL CENTER   (United States)

^g LEVINE CANCER INSTITUTE   (United States)

^h MIDDELHEIM HOSPITAL   (Belgium)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j Austin Heart   (United States)

^k Heart and Vascular Institute   (United States)

^l North Ohio Heart Center   (United States)

^m ST VINCENT HOSPITAL   (United States)

ⁿ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^o Foundation for Cardiovascular Medicine   (United States)

^p CARDIOVASCULAR CENTER   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; PLACEBO; POLYMER;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FOLLOW UP; HEART BLOOD VESSEL; HEART DEATH; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVASCULARIZATION; SINGLE BLIND PROCEDURE; THROMBOSIS;

ABSORBABLE IMPLANTS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHROMIUM ALLOYS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PLATELET AGGREGATION INHIBITORS; POLYMERS; RISK; THROMBOEMBOLISM; TICLOPIDINE; TIME FACTORS;

EID: 41949127381     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.01.020     Document Type: Article

References (19)

1. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
2. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
3. Camenzind E., Steg P.G., and Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 115 (2007) 1440-1455
4. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
5. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168
6. Laskey W.K., Yancy C.W., and Maisel W.H. Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7-8, 2006. Circulation 115 (2007) 2352-2357
7. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
8. Finn A.V., Nakazawa G., Joner M., et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 27 (2007) 1500-1510
9. Serruys P.W., Sianos G., Abizaid A., et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 46 (2005) 253-260
10. Conor MedSystems, LLC. COSTAR 1: The COSTAR INDIA Trial-Cobalt Chromium Stent With Antiproliferative for Restenosis in India trial. Corporate communication. Paper presented at: Transcatheter Therapeutics; October 21, 2005; Washington, DC.
11. Dawkins K., Verheye S., Shuhlen H., et al. The European Cobalt Stent with Antiproliferative for Restenosis trial. (EUROSTAR): 12 month results. EuroIntervention 3 (2007) 82-88
12. Wang T.Y., Hasselblad V., Peterson J.L., et al. The Cobalt Chromium Stent With Antiproliferative for Restenosis II (COSTAR II) trial study design: advancing the active-control evaluation of second-generation drug-eluting stents. Am Heart J 153 (2007) 743-748
13. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
14. Kataoka T., Grube E., Honda Y., et al. 7-hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the Study to Compare Restenosis Rate Between Quest and Quads-QP2 (SCORE). Circulation 106 (2002) 1788-1793
15. Hasselblad V., and Kong D.F. Statistical methods for comparison to placebo in active-control trials. Drug Inf J 35 (2001) 435-449
16. Stone G.W., Ellis S.G., Cannon L., Mann J.T., and Taxus V Investigators. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 294 (2005) 1215-1223
17. Dawkins K.D., Grube E., Guagliumi G., and TAXUS VI Investigators. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 112 (2005) 3306-3313
18. Kereiakes D.J., Kuntz R.E., Mauri L., and Krucoff M.W. Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. J Am Coll Cardiol 45 (2005) 1206-1212
19. Krucoff M.W., Boam A., and Schultz D.G. Drug-eluting stents "deliver heartburn": how do we spell relief going forward?. Circulation 115 (2007) 2990-2994